Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Free Report) have been assigned an average rating of “Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $10.00.
Several research firms have commented on IPSC. Piper Sandler dropped their price objective on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating for the company in a research note on Monday, December 30th. Guggenheim reaffirmed a “buy” rating on shares of Century Therapeutics in a research note on Wednesday. Chardan Capital reduced their price objective on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Century Therapeutics in a research report on Wednesday.
Get Our Latest Stock Analysis on IPSC
Century Therapeutics Trading Down 1.1 %
Century Therapeutics (NASDAQ:IPSC – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. The business had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. During the same period last year, the company earned ($0.55) EPS. As a group, equities analysts forecast that Century Therapeutics will post -1.63 EPS for the current year.
Hedge Funds Weigh In On Century Therapeutics
A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Century Therapeutics by 110.1% in the second quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock valued at $380,000 after purchasing an additional 78,088 shares during the period. Rhumbline Advisers increased its holdings in Century Therapeutics by 56.0% during the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after purchasing an additional 18,828 shares during the period. Dimensional Fund Advisors LP raised its position in Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock valued at $192,000 after purchasing an additional 44,155 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Century Therapeutics by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 165,500 shares of the company’s stock worth $422,000 after buying an additional 9,500 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Century Therapeutics during the 3rd quarter worth $27,000. 50.20% of the stock is owned by hedge funds and other institutional investors.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Further Reading
- Five stocks we like better than Century Therapeutics
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What Does a Stock Split Mean?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- 3 Dividend Kings To Consider
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.